CAR-T cell capable of secreting PD-1 single-domain antibody targeting FAP as well as preparation method and application of CAR-T cell
By constructing CAR-T cells that secrete PD-1 single-domain antibodies to target FAP, using chimeric antigen receptors and lentiviral infection technology, the problem of CAR-T cells being inhibited in solid tumor treatment was solved, and the problem of CAR-T cells being suppressed was achieved. Efficient targeting and killing of FAP-positive tumors.
Patent Information
- Application Number
- CN202310503193.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-06
- Publication Date
- 2024-11-08
AI Technical Summary
In the treatment of solid tumors, the function of CAR-T cells is affected by the tumor's complex immunosuppressive microenvironment, resulting in poor efficacy. In addition, traditional single-chain antibodies have problems such as light chain and heavy chain mismatch during targeting, which is difficult to be effective Targeting tumors.
CAR-T cells that secrete PD-1 single-domain antibody targeting FAP were constructed, and T cells modified by chimeric antigen receptor FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP were used, and lentiviral infection technology was used. Preparation is carried out to ensure stable expression and efficient targeting of chimeric antigen receptors.
It enhances the specific recognition and killing activity of CAR-T cells on tumor antigens, improves the infiltration ability in the tumor site, reduces T cell depletion, and achieves effective targeted treatment for FAP-positive tumors.
Smart Images

Figure CN118909949A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of tumor biological products, and relates to a CAR-T cell (FAP-PD-1 / Nb CAR-T cell) that secretes a PD-1 single domain antibody targeting FAP in adoptive immunotherapy, and a preparation method and application thereof. Background Art
[0002] In recent years, breakthroughs have been made in tumor treatment, and immunotherapy is currently one of the hot spots in tumor treatment. T cells are important anti-tumor immune cells in the human body, and the human body recognizes tumor antigens through T cell receptors (TCR). However, not all TCRs can target tumor antigens, so people use genetic engineering technology to equip T cells with chimeric antigen receptors (CAR) that specifically recognize tumor antigens to express receptors for tumor antigens and then target tumors for new immune therapies. In 2017, the CAR-T treatment product Kymriah was launched on the market and was used for the first time to treat blood tumors, achieving good results. However, in the treatment of solid tumors, the complex immunosuppressive microenvironment of the tumor and other factors inhibit the function of CAR-T cells, making CAR-T relatively slow in this field.
[0003] Cancer-associated fibroblasts (CAFs) are a type of abnormally differentiated stromal cells that occupy the majority of cells in the tumor immunosuppressive microenvironment. Fibroblast activation protein (FAP) is a specific marker of CAFs, which is expressed in some tumor cells and stromal cells.
[0004] Programmed death-1 (PD-1) is a negative regulatory protein for T cell activation. It binds to programmed death ligands 1 and 2 (PD-L1 and PD-L2) to inhibit T cell activation. Drugs targeting this pathway help reactivate T cells and reactivate anti-tumor immune responses. PD-1 monoclonal antibody drugs can enhance the anti-tumor effect of T cells and have achieved good results in clinical applications. This study aims to achieve better therapeutic effects in the treatment of solid tumors by constructing CAR-T cells with strong activity that simultaneously targets the tumor microenvironment and tumor cells.
[0005] In addition, the key components of CAR-T cell targeting are currently mainly single-chain antibodies (Single chain variable fragment, scFv). Traditional single-chain antibodies are prone to light chain and heavy chain mismatch and need to optimize the hinge region. Nanobody (Nb) (single domain antibody) is a new type of natural antibody discovered in recent years. It has the advantages of small size, easy expression, good solubility, and strong stability. It has broad research prospects in basic research, new drug development, disease diagnosis and treatment, and has become the object of research and development in various countries. The present invention successfully constructed CAR-T cells (FAP-PD-1 / Nb CAR-T cells) that secrete PD-1 single domain antibodies targeting FAP, and explored its therapeutic effect in solid tumors. Summary of the invention
[0006] An object of the present invention is to provide an engineered CAR-T cell that secretes a PD-1 single domain antibody targeting FAP, and another object is to provide a method for preparing the CAR-T cell and to provide the use of the CAR-T cell in preparing a preparation for treating a tumor.
[0007] To achieve the above object, the present invention adopts the following technical solutions:
[0008] A CAR-T cell engineered to secrete a PD-1 single domain antibody targeting FAP, wherein the CAR-T cell is a T cell modified with a chimeric antigen receptor FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP.
[0009] The CAR-T cells that secrete PD-1 single domain antibodies targeting FAP, wherein the nucleotide sequence of the chimeric antigen receptor FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP is shown in SEQ ID NO.1 in the sequence table.
[0010] A method for preparing the CAR-T cell, the method comprising the following steps: designing a CAR target sequence, obtaining a CAR target sequence fragment of FAP / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES-GFP by PCR, recombining a lentiviral vector after enzyme digestion with the CAR target sequence obtained by PCR, transforming the recombinant lentiviral vector into Escherichia coli, and screening positive clones, sequencing the positive clones to verify whether a lentiviral vector containing a FAP-PD-1 / Nb CAR sequence is successfully constructed, extracting plasmids from the recombinant positive clone strains that have been successfully sequenced, transfecting them into cells to be transfected, identifying the expression of the FAP-PD-1 / Nb CAR sequence in the cells by RT-PCR, verifying that the recombinant lentiviral vector can be expressed normally and then packaging the lentivirus, preparing T cells, and constructing the CAR-T cell by lentiviral infection technology.
[0011] A method for preparing the CAR-T cells as described above, the method comprising the following steps:
[0012] (1) Construction of a recombinant lentiviral vector containing the CAR target sequence: The CAR target sequence fragment of FAP / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES-GFP was obtained by PCR, and the synthesized fragment was subcloned into the lentiviral vector GV400 after BamHI / EcoRI double digestion. The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the colonies screened with ampicillin were identified by PCR using primers on the lentiviral vector and primers on the target gene. The successfully identified bacterial liquid was sequenced, and the plasmid was extracted using the Plasmid Mini Kit after sequencing to obtain a plasmid containing the CAR target sequence;
[0013] (2) Lentivirus packaging: Using a three-plasmid system, the plasmid containing the CAR target sequence was co-transfected into 293T cells through two auxiliary plasmids Helper1.0 and Helper2.0. After 48 hours, the green fluorescent protein (GFP) expression of the cells was observed under a fluorescence microscope. If fluorescence was successfully expressed, the 293T cell supernatant was collected and concentrated and purified. The virus concentration was determined by the fluorescence dilution method, and the number of green fluorescent protein-positive cells was counted. The virus titer was calculated according to the formula: virus concentration = number of fluorescent cells / volume of virus stock solution in the well;
[0014] (3) T cell preparation: Isolate mononuclear cells from peripheral blood and culture them to obtain T cells;
[0015] (4) Preparation of FAP-PD-1 / Nb CAR-T cells: T cells were cultured for 24 hours using a dedicated T cell culture medium containing human CD3 monoclonal antibody, human CD28 monoclonal antibody, and human IL-2 cytokine. The next day, lentivirus solution was added to the stimulated T cells at an MOI of 20 and cultured in a 37°C CO2 incubator for 48 hours. The CAR-T cells were placed under a conventional microscope to observe the GFP expression of the CAR-T cells.
[0016] In step (4), when the amount of T cells infected by the lentivirus accounts for 80-90% of the culture flask, the cells are collected and the medium is replaced, and complete culture medium with a final concentration of 100 U / mL of IL-2 is added for amplification culture, and the infected cells are identified by flow cytometry.
[0017] As in the preparation method described above, the CAR-T cells are prepared using lentiviral infection technology.
[0018] A use of the CAR-T cells that secrete PD-1 single-domain antibodies targeting FAP in the preparation of preparations for treating tumors.
[0019] As in the above application, preferably, the tumor is a FAP-positive tumor.
[0020] A pharmaceutical composition comprising the CAR-T cells that secrete PD-1 single domain antibodies targeting FAP and a pharmaceutically acceptable carrier.
[0021] A nucleotide sequence encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP.
[0022] A chimeric antigen receptor, wherein the chimeric antigen receptor is FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP.
[0023] The researchers of the present invention found that in the immunotherapy of FAP-positive tumors, the advantage of CAR-T cells that secrete PD-1 single-domain antibodies targeting FAP is specific targeting, that is, enhancing the targeted recognition of tumor antigens by immune cells. In addition, it also enhances the tumor killing activity dependent on the chimeric antigen receptor and the infiltration at the tumor site after infusion, reducing T cell exhaustion. These characteristics of FAP-PD-1 / Nb CAR-T originate from the functional structure of the chimeric antigen receptor, which mainly includes the antigen recognition region and the intracellular activation region. The intracellular activation region can prolong the survival time of cells in vivo. In addition, the present invention uses lentiviral infection to prepare CAR-T cells, and provides a method for efficiently preparing FAP-PD-1 / Nb CAR-T. The CAR-T prepared by this method can stably express the chimeric antigen receptor and has a good application prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is the gel electrophoresis diagram of the FAP-PD-1 / Nb CAR gene sequence synthesized by PCR in Example 2 of the present invention, M: Marker; 1: PCR product of the target gene.
[0025] Figure 2 Schematic diagram of the recombinant lentiviral vector in Example 3 of the present invention.
[0026] Figure 3 This is the PCR identification diagram of the DH5α positive clone colony in Example 3 of the present invention, wherein 1-2: negative control (ddH2O); 3: positive control; 4: Markers from top to bottom are 5kb, 3kb, 2kb, 1.5kb, 1Kb, 750bp, 500bp, 250bp, 100bp; 5-12: positive transformants or empty vector self-ligation groups (10).
[0027] Figure 4 It shows that the T cells in Example 5 of the present invention express GFP fluorescence after lentiviral transfection.
[0028] Figure 5 The expression of CAR after lentiviral transfection of T cells in Example 5 of the present invention is shown.
[0029] Figure 6 The results show that the T cells in Example 5 of the present invention secrete PD-1 single domain antibodies after lentiviral transfection.
[0030] Figure 7 It shows that the FAP-PD-1 / Nb CAR-T in Example 6 of the present invention specifically kills FAP-positive tumor cells. DETAILED DESCRIPTION
[0031] The present invention is further described in detail below in conjunction with specific embodiments. The examples given are only for illustrating the present invention, but not for limiting the scope of the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0032] Example 1 Preparation and activation of T cells
[0033] (1) Density gradient centrifugation to separate peripheral blood T lymphocytes
[0034] Fresh peripheral blood was collected from healthy volunteers using a blood collection tube with anticoagulant, and an equal volume of peripheral blood was mixed with PBS at 37°C. Peripheral blood T lymphocytes were separated by density gradient centrifugation. 4 ml of 37°C sterile lymphocyte separation solution was drawn into a 15 ml centrifuge tube, and 8 ml of diluted peripheral blood was slowly added to the separation liquid surface along the wall of the centrifuge tube. Centrifuge at 2000 rpm for 20 minutes. After the centrifugation, the tube was divided into four layers. The cloudy white film layer cells (PBMC) were carefully drawn along the edge of the centrifuge tube with a Pasteur tube, and the cell suspension was collected into a sterile 50 ml centrifuge tube. Four times the volume of PBS was added and the cells were washed twice. The collected PBMC cells were resuspended with complete cell culture medium RIPM 1640, transferred to a cell culture dish, and cultured in a 37°C cell culture incubator for 2 hours. The suspended cells in the cell culture dish were drawn into another culture dish for culture. The suspended cells were T lymphocytes. T lymphocytes were cultured with complete RIPM 1640 medium containing 100 U / ml rhIL-2.
[0035] (2) T cell culture
[0036] T cells were cultured for 24 hours using a dedicated T cell culture medium containing human CD3, human CD28 monoclonal antibodies, and human IL-2 cytokine.
[0037] Example 2 PCR synthesis of CAR target gene sequence
[0038] The target gene sequence was synthesized and amplified by PCR, and the primers were shown in Table 1 to obtain the CAR fragment of FAP / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES-GFP, and finally the band of the target fragment was obtained, as shown in Figure 1 shown.
[0039] Table 1
[0040] ID seq Identification primer-F CCAAAGGAATGCAAGGTCTG Identification primer-R AGCGTAAAAGGAGCAACATAG
[0041] Example 3 Construction of recombinant lentiviral vector
[0042] The GV400 vector was digested by double enzyme digestion. After digestion, agarose gel electrophoresis showed that the molecular weight of the lentiviral vector plasmid after digestion was about 8Kd, and the band was clear. The lentiviral vector after digestion was recombined with the CAR target sequence obtained by PCR in Example 2 to obtain a recombinant lentiviral vector, such as Figure 2 The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the target gene were used to perform PCR identification on the colonies screened with ampicillin antibiotics. The PCR product electrophoresis was as shown in Figure 3 As shown, it indicates that the lentiviral recombinant vector plasmid containing the target CAR sequence was successfully constructed. The positive clone bacteria were sequenced and compared to be completely consistent with the target sequence.
[0043] Example 4 Lentivirus packaging
[0044] The recombinant positive clones that were successfully sequenced were extracted with the Plasmid Mini Kit and transfected into 293T cells. The expression of the FAP-PD-1 / Nb CAR gene sequence in 293T cells was quantitatively examined and analyzed using a real-time fluorescence quantitative nucleic acid amplification detector (Real-time Quantitative PCR Detecting System). The recombinant lentiviral vector containing the CAR sequence was co-transfected into 293T cells using a three-plasmid system through two auxiliary vector plasmids (Helper 1.0 and Helper 2.0). After 48 hours, the cells were observed under a fluorescence microscope and obvious green fluorescence (GFP) was observed. The supernatant of 293T cells was collected, concentrated and purified, and the virus concentration was determined by the fluorescence dilution method. The number of GFP-positive cells was counted, and the virus titer was calculated according to the formula virus concentration = number of fluorescent cells / volume of the virus stock solution in the well.
[0045] Example 5 Construction of CAR-T cells that secrete PD-1 single domain antibody targeting FAP (FAP-PD-1 / Nb CAR-T cells)
[0046] (1) Lentiviral infection of T lymphocytes
[0047] T cells were plated into 24-well plates and the cell density in each well was adjusted to 1×10 7 The cells were cultured in a special medium containing 10% FBS, human CD3 monoclonal antibody, human CD28 monoclonal antibody and human IL-2 cytokine for 24 hours, and the lentivirus was added to the stimulated T cells at an MOI of 20. After 48 hours, the expression of GFP was observed under a fluorescence microscope. Figure 4 As shown, Utd represents untransfected T cells (as a negative control) and Mock represents CAR-T cells without extracellular recognition receptors.
[0048] (2) Flow cytometry detection of the expression of CAR targeting FAP in T cells secreting PD-1 single domain antibody
[0049] Collect 1×10 6 After lentiviral transfection, FAP-PD-1 / Nb CAR-T cells, CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells (Utd as negative control) were incubated with PE-anti His tag antibody in the dark, washed three times with PBS, and the expression of HIS-TAG and GFP fluorescent protein on the surface of CAR-T in each group was simultaneously detected by flow cytometry. The results showed that the chimeric antigen receptor was expressed in T cells, such as Figure 5 shown.
[0050] (3) ELISA detection of CAR secretion of PD-1 single domain antibody targeting FAP
[0051] The PD-1 single domain antibody secreted by FAP-PD-1 / Nb CAR-T is labeled with HIS-TAG. The ELISA method was used to detect the content of HIS-TAG in the culture supernatant of each group of CAR-T cells to determine the secretion of PD-1 single domain antibody. 1×10 6 FAP-PD-1 / Nb CAR-T cells transfected with lentivirus and CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells Utd as negative control, the specific operation steps are as follows:
[0052] a. Prepare standard samples as required, with a maximum concentration of 200 pg / mL.
[0053] b. Soaking the ELISA plate: Take out the strips to be used, add 300 μL of washing solution to each well and let it soak for 30 seconds, then pat dry on absorbent paper.
[0054] c. Sample addition: Add 200 μL of standard to the standard wells, add 100 μL of cell culture medium to the blank wells, and add 100 μL of the supernatant of the cells to be tested to each sample well.
[0055] d. Add detection antibody: Add 50 μL of diluted antibody to each well, and try to ensure that the sample and detection antibody are added within 15 minutes.
[0056] e. Incubation: Seal the plate with a sealing film and incubate at room temperature with shaking at 300 rpm for 2 h.
[0057] f. Washing: discard the liquid in the well, add 300μL 1× washing solution, let stand for 1min, discard the liquid in the well. Then pat dry thoroughly on absorbent paper. Wash 6 times.
[0058] g. Add horseradish peroxidase: Add 100 μL of horseradish peroxidase-labeled streptavidin working solution to each well.
[0059] h. Incubation: Seal the plate with a new sealing film and incubate at room temperature with shaking at 300 rpm for 45 min.
[0060] i. Add substrate for color development: Add 100 μL of color development substrate TMB working solution to each well and incubate for 30 minutes in the dark.
[0061] j. Add stop solution: Add 100 μL of stop solution to each well. The liquid in the well will turn from blue to yellow. Mix thoroughly.
[0062] k. Result detection: Within 30 minutes, use an ELISA reader to perform dual wavelength detection, measure the maximum absorption wavelength of 450nm and analyze the data. Figure 6 As shown, in order to prove the secretion of PD-1Nb by CAR T cells, the CAR T cell culture fluid was collected at different time points and the expression of PD-1Nb was detected by ELISA, and the CAR T cells were collected and the expression of PD-1Nb was detected by WB. The results showed that the PD-1 / Nb CAR T cell group, Irrelevant-PD-1 / Nb CAR T cell group, and FAP-PD-1 / Nb CAR T cell group could continuously secrete PD-1Nb, reaching a peak on the sixth day.
[0063] Example 6 Cytotoxicity analysis of FAP-PD-1 / N b CAR-T on human tumor cells
[0064] The expression of FAP in liver cancer cells HepG2-hFAP, HepG2, and U87 was stained with PKH26. Figure 7 As shown. Take the FAP-PD-1 / Nb CAR-T cells prepared in Example 5 and the T cells cultured in Example 1 respectively, and add the corresponding number of effector T lymphocytes and target cells to a 24-well plate at an effector-target ratio (E:T) of 1:1, 5:1, and 10:1, respectively. After culturing for 16 hours, collect the above cells, add PI dye solution, and incubate at 4°C in the dark for 30 minutes. Centrifuge at 1200rpm for 6 minutes in a high-speed centrifuge, remove the supernatant, add 500μl of PBS to resuspend the cells, PKH26+PI+ is the dead cell, and the proportion of PKH26+PI+ cells is detected by flow cytometry. The killing efficiency of CAR-T cells on different cells is calculated according to the formula. Among them, the killing rate = 100% × (apoptosis rate of experimental wells - apoptosis rate of natural release wells) / (100 - apoptosis rate of natural release wells), and the natural release wells are target cells without effector cells. As shown Figure 7As shown, FAP-PD-1 / Nb CAR-T cells have specific killing activity against tumor cells with high expression of FAP.
Claims
1. A CAR-T cell that secretes a PD-1 single domain antibody targeting FAP, characterized in that: The CAR-T cell is a T cell modified by the chimeric antigen receptor FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP, and the nucleotide sequence of the chimeric antigen receptor FAPNb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP comprises the nucleotide sequence shown in SEQ ID NO.
1.
2. The CAR-T cell according to claim 1, wherein the nucleotide sequence of the chimeric antigen receptor FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP is the nucleotide sequence shown in SEQ ID NO.
1.
3. A method for preparing CAR-T cells according to claim 1, characterized in that: The method comprises the following steps: designing a CAR target sequence, obtaining a CAR target sequence fragment of FAP / Nb-HIStag-CD8-CD137-CD3ζ-2A-PD-1Nb-IRES-GFP by PCR, recombining a lentiviral vector after enzyme digestion with the CAR target sequence obtained by PCR, transforming the recombinant lentiviral vector into Escherichia coli, screening positive clones, sequencing the positive clones to verify whether a lentiviral vector containing a FAP-PD-1 / Nb CAR sequence is successfully constructed, extracting plasmids from the recombinant positive clone strains that have been successfully sequenced, transfecting them into cells to be transfected, identifying the expression of the FAP-PD-1 / Nb CAR sequence in the cells by RT-PCR, verifying that the recombinant lentiviral vector can be expressed normally, and then packaging the lentivirus, preparing T cells, and constructing the CAR-T cells by using lentiviral infection technology.
4. A method for preparing CAR-T cells according to claim 3, characterized in that: The method comprises the following steps: (1) Construction of a recombinant lentiviral vector containing the CAR target sequence: The CAR target sequence fragment of FAP / Nb-HIStag-CD8-CD137-CD3ζ-2A-PD-1Nb-IRES-GFP was obtained by PCR, and the synthesized fragment was subcloned into the lentiviral vector GV400 after BamHI / EcoRI double digestion. The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the primers on the target gene were used to perform PCR identification on the colonies selected by ampicillin antibiotics. The successfully identified bacterial liquid was sequenced. After successful sequencing, the plasmid was extracted using the Plasmid Mini Kit to obtain a plasmid containing the CAR target sequence; (2) Lentivirus packaging: Using a three-plasmid system, the plasmid containing the CAR target sequence was co-transfected into 293T cells through two helper plasmids Helper1.0 and Helper2.
0. After 48 hours, the green fluorescent protein expression of the cells was observed under a fluorescence microscope. If fluorescence was successfully expressed, the 293T cell supernatant was collected and concentrated and purified. The virus concentration was determined by the fluorescence dilution method, and the number of green fluorescent protein-positive cells was counted. The virus titer was calculated according to the following formula: virus concentration = number of fluorescent cells / volume of virus stock solution; (3) T cell preparation: Isolate mononuclear cells from peripheral blood and culture them to obtain T cells; (4) Preparation of FAP-PD-1 / Nb CAR-T cells: T cells were cultured for 24 hours in a dedicated T cell culture medium containing human CD3 monoclonal antibody, human CD28 monoclonal antibody and human IL-2 cytokine. The next day, lentivirus solution was added to T cells at an MOI of 20 and cultured in a 37°C CO2 incubator for 48 hours. The CAR-T cells were placed under a conventional microscope to observe the expression of green fluorescent protein in the CAR-T cells.
5. The preparation method according to claim 4, wherein in step (4), when the amount of T cells infected by the lentivirus accounts for 80-90% of the culture flask, the cells are collected and the medium is replaced, and a complete culture medium with a final concentration of 100 U / mL of IL-2 is added for amplification culture, and the infected cells are identified by flow cytometry.
6. Use of the CAR-T cells that secrete the PD-1 single domain antibody targeting FAP as claimed in claim 1 or 2 in the preparation of a preparation for treating tumors.
7. The use according to claim 6, wherein the tumor is a FAP-positive tumor.
8. A pharmaceutical composition comprising the CAR-T cell according to claim 1 or 2 and a pharmaceutically acceptable carrier.
9. A nucleotide sequence encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP, and the nucleotide sequence is SEQ ID NO.
1.
10. A chimeric antigen receptor, wherein the chimeric antigen receptor is FAP Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP, and the chimeric antigen receptor is encoded by the nucleotide sequence shown in SEQ ID NO.1.
Citation Information
Cited By
Bispecific antibody, genetically modified TIL cell and construction method and application of genetically modified TIL cell
CN120484128A
A bispecific antibody, genetically modified TIL cells, and methods of construction and use thereof
CN120484128B
